Completed PHASE2 INTERVENTIONAL 1-arm NCT03507166

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

A Multicenter, Open Label，Single Arm，Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Sponsor: RemeGen Co., Ltd.

Conditions Advanced Cancer Urothelial Carcinoma

Interventions RC48-ADC

Updated 9 times since 2018 Last updated: Aug 20, 2019 Started: Dec 28, 2017 Primary completion: Oct 29, 2018 Completion: Oct 29, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Advanced Cancer and Urothelial Carcinoma, this trial is completed. The trial is conducted by RemeGen Co., Ltd. and has accumulated 9 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Oct 2021 [monthly]

Completed PHASE2
Sep 2019 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jul 2019 — Sep 2019 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Feb 2019 — Jul 2019 [monthly]

Recruiting PHASE2
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Dec 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

RemeGen Co., Ltd.

Data source: RemeGen Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China